Fist Assist Devices, LLC Announces Release of the p-FACT Cohort Data

Fist Assist Devices, LLC, announces that data associated with the p-FACT cohort, a data subset of the recently completed, non-significant risk Fist Assist Clinical Trial (FACT Trial) that focused on vein dilation in stage 4 patients with chronic renal failure, shows clear evidence that the Fist Assist device dilates the perforator vein. The p-FACT data derived from the FACT trial evaluated the use the FA-1 device developed by Fist Assist Devices, LLC, a novel, intermittent pneumatic compression device, to promote superficial vein dilation in patients with chronic kidney disease to enable creation of all types of arteriovenous fistulas and to ensure the safety of the device in this patient population.

We are thrilled to announce the results of the p-FACT data. The statistically significant data, with a p value of <.05, shows that the FA-1 device clearly dilates the perforator vein in stage 4 chronic renal failure patients,” said Tej Singh M.D., M.B.A., Chief Executive Officer and Founder of Fist Assist Devices, LLC. “This is very important data as it not only shows that the FA-1 device is safe, the data also demonstrates that intermittent pneumatic pressure dilates superficial veins including, most importantly, the perforator vein needed for EndoAVF success. Condition of the perforator vein is critical for EndoAVF planning, and we can now show without a doubt that the Fist Assist FA-1 device can dilate that clinically important vein and have a key role in EndoAVF consideration and planning!”

“This is revolutionary data for the ESRD community, namely the patients, physicians, and companies associated with EndoAVF procedures,” said Greenwood, Mississippi vascular access surgeon and FACT Investigator Dr. John Lucas. “Larger veins not only make vascular access surgery easier and more likely to succeed, but a larger, dilated perforator vein is essential for the EndoAVF to mature properly. Both EndoAVF technologies presently approved and available for treatment of end stage renal disease utilize the perforator vein as a key component of the procedure. The statistically significant p-FACT data demonstrates that intermittent compression results in a larger perforator vein for stage 4 patients. Based on the FACT Trial p-FACT data, almost every stage 4 renal disease patient planning to have having an EndoAVF procedure should consider using the FA-1 device in preparation for their procedure. Larger veins, especially the perforator vein, will surely improve outcomes! This is very exciting data for all patients and the global ESRD community.”

Exit mobile version